SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of ...
United Therapeutics UTHR reported fourth-quarter 2025 earnings per share (EPS) of $7.70, which surpassed the Zacks Consensus Estimate of $6.78. Earnings increased 24% year over year, driven by higher ...
Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression “Completing enrollment in this trial brings us one step ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug ...
A new FDA approval for United Therapeutics Corp.'s prostacyclin analogue, Tyvaso (treprostinil), has expanded its label to include the treatment of pulmonary hypertension associated with interstitial ...
MannKind Corp. MNKD said Tuesday it has entered a royalty agreement with Sagard Healthcare under which the latter will receive 1% of royalty sales of Tyvaso DPI inhalation powder for up to $200 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results